Q1 Net Loss Improves, $13.9M Public Offering Completed, and Authorized Shares Corrected to 2 Billion
PSTV sits 77% above its 52-week low of $2.9.
Summary
PLUS THERAPEUTICS, INC. reported improved Q1 net loss, completed a $13.9 million public offering, repaid a $4.5 million investor liability, and corrected its authorized shares to 2 billion, while still facing a 'going concern' warning.
Key Events · Financing and Capital Events · PSTV
-
Q1 Net Loss Significantly Reduced
The company reported a net loss of $6.9 million for the first quarter of 2026, a substantial improvement from the $17.4 million net loss in Q1 2025, largely due to lower non-cash financing expenses.
-
Successful $13.9M Public Offering
In January 2026, the company completed an underwritten public offering, raising approximately $13.9 million in net proceeds, which is critical for its liquidity and operations.
-
Working Capital Boost and Debt Repayment
Working capital increased to $10.1 million as of March 31, 2026, from $2.9 million at December 31, 2025. The company also repaid a $4.5 million investor liability, leading to the cancellation of 272,821 shares.
-
Authorized Shares Corrected to 2 Billion
A Certificate of Correction filed on May 12, 2026, clarified that the total authorized common stock is 2 billion shares, not 200 million, providing extensive flexibility for future equity raises.
Analysis · PSTV · Industrial Applications And Services
PLUS THERAPEUTICS, INC. reported a significantly reduced net loss of $6.9 million for Q1 2026, compared to $17.4 million in Q1 2025, primarily due to the absence of large non-cash financing expenses and derivative fair value changes seen in the prior year. The company successfully completed a public offering in January 2026, raising $13.9 million in net proceeds, which is crucial given its ongoing cash burn and 'going concern' warning. Working capital improved substantially to $10.1 million from $2.9 million at year-end 2025. The company also repaid a $4.5 million investor liability and regained Nasdaq bid price compliance following a 1-for-25 reverse stock split. A subsequent filing corrected the authorized common stock from 200 million to 2 billion shares, providing significant headroom for future capital raises but also indicating substantial potential for dilution.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PSTV was trading at $5.13 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $36M. The 52-week trading range was $2.90 to $23.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.